BioNTech Management
Management criteria checks 4/4
BioNTech's CEO is Ugur Sahin, appointed in Jan 2008, has a tenure of 16.83 years. total yearly compensation is €3.06M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 17.23% of the company’s shares, worth CHF4.18B. The average tenure of the management team and the board of directors is 3.3 years and 4.6 years respectively.
Key information
Ugur Sahin
Chief executive officer
€3.1m
Total compensation
| CEO salary percentage | 22.9% |
| CEO tenure | 16.8yrs |
| CEO ownership | 17.2% |
| Management average tenure | 3.3yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -€467m |
| Jun 30 2024 | n/a | n/a | -€504m |
| Mar 31 2024 | n/a | n/a | €113m |
| Dec 31 2023 | €3m | €700k | €930m |
| Sep 30 2023 | n/a | n/a | €3b |
| Jun 30 2023 | n/a | n/a | €4b |
| Mar 31 2023 | n/a | n/a | €6b |
| Dec 31 2022 | €6m | €360k | €9b |
| Sep 30 2022 | n/a | n/a | €10b |
| Jun 30 2022 | n/a | n/a | €12b |
| Mar 31 2022 | n/a | n/a | €13b |
| Dec 31 2021 | €12m | €360k | €10b |
| Sep 30 2021 | n/a | n/a | €7b |
| Jun 30 2021 | n/a | n/a | €4b |
| Mar 31 2021 | n/a | n/a | €1b |
| Dec 31 2020 | €17m | €360k | €15m |
| Sep 30 2020 | n/a | n/a | -€410m |
| Jun 30 2020 | n/a | n/a | -€230m |
| Mar 31 2020 | n/a | n/a | -€192m |
| Dec 31 2019 | €7m | €311k | -€179m |
| Sep 30 2019 | n/a | n/a | -€122m |
| Jun 30 2019 | n/a | n/a | -€116m |
| Mar 31 2019 | n/a | n/a | -€77m |
| Dec 31 2018 | €653k | €210k | -€48m |
Compensation vs Market: Ugur's total compensation ($USD3.18M) is below average for companies of similar size in the Swiss market ($USD4.73M).
Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.
CEO
Ugur Sahin (59 yo)
16.8yrs
Tenure
€3,056,000
Compensation
Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 16.8yrs | €3.06m | 17.23% CHF 4.2b | |
| Co-Founder | 6.8yrs | €814.00k | 0.38% CHF 92.4m | |
| CFO & Member of Management Board | 3.3yrs | €1.32m | 0.00068% CHF 164.9k | |
| MD, COO & Member of Management Board | 10.8yrs | €821.00k | 0.31% CHF 76.4m | |
| Chief Strategy Officer | 4.8yrs | €1.41m | 0.0061% CHF 1.5m | |
| Chief Legal & Business Officer & Member of the Management Board | 1.2yrs | €848.00k | no data | |
| Executive Officer | less than a year | €133.00k | 0.34% CHF 82.5m | |
| Senior Vice President of Global Financial Reporting & Accounting | less than a year | no data | no data | |
| Senior Vice President of Corporate Development & Strategy | less than a year | no data | no data | |
| Senior VP & External Consultant for RNA Protein Replacement Therapies | no data | no data | no data | |
| Senior Vice President of Operations | no data | no data | no data | |
| Senior Vice President of Immunotherapy & Preclinical Research | no data | no data | no data |
3.3yrs
Average Tenure
57yo
Average Age
Experienced Management: 22UA's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Supervisory Board Member | 2.4yrs | €90.00k | 0.00017% CHF 41.2k | |
| Independent Deputy Chairman Supervisory Board | 6.8yrs | €114.00k | no data | |
| Independent Supervisory Board Member | 16.8yrs | €80.00k | no data | |
| Independent Supervisory Board Chairman | 16.8yrs | €226.00k | 0.14% CHF 33.6m | |
| Member of Supervisory Board | 1.5yrs | €46.00k | no data | |
| Supervisory Board Member | 2.4yrs | €105.00k | 0.00010% CHF 24.3k |
4.6yrs
Average Tenure
58.5yo
Average Age
Experienced Board: 22UA's board of directors are considered experienced (4.6 years average tenure).